Nucleoside reverse transcriptase inhibitors (NTRIs) were developed to treat HIV infection, interfering in the ability of the virus to replicate. Researchers here present epidemiological evidence for this class of drug to slow the onset of Alzheimer’s disease. The researchers focus on reduced inflammation as a driving mechanism, but it seems plausible that this outcome occurs because NTRI’s interfere in harmful transposable element activities. Transposable elements such as retrotransposons are largely the genetic remnants…
Nucleoside Reverse Transcriptase Inhibitors May Slow the Development of Alzheimer's Disease
Nucleoside reverse transcriptase inhibitors (NTRIs) were developed to treat HIV infection, interfering in the ability of the virus to replicate. Researchers here present epidemiological evidence for this class of drug to slow the onset of Alzheimer’s disease. The researchers focus on reduced inflammation as a driving mechanism, but it seems plausible that this outcome occurs because NTRI’s interfere in harmful transposable element activities. Transposable elements such as retrotransposons are largely the genetic remnants…